For over 60 years, Tunnell has provided both expert talent and consulting services to clients including Biopharmas, CDMOs, the US Government, incubators, investors and NGOs. We have experience across multiple platforms – including large molecule, vaccines, cell and gene therapy and small molecule – and our subject matter expertise focuses on regulatory, quality, GxP, pre-clinical/clinical, supply chain, manufacturing, CMC and product launch. To learn more, visit us online at http://www.tunnellconsulting.com.
Trialmed
Trialmed is the trusted clinical trial partner for patients, trial volunteers and sponsors/CROs. We facilitate clinical research as a care option for patients and healthy volunteers as a part of their health care journey. We create holistic experiences that put the patient first through our welcoming clinics, user-friendly digital technology, and our relentless focus on total quality delivery. Our patient-first approach makes Trialmed the clinical research destination of choice for patients and healthy volunteers. With extensive access to patients in the geographies where we operate, Trialmed ensures reliable enrollment outcomes that consistently meet or exceed sponsor expectations. We offer Home Trial Services for the ultimate in patient flexibility — conducting clinical trial visits where the patient prefers, such as the patient’s home, office or school. Our flexible clinical trial solutions scale to the sponsor’s needs and budget, offering a best-in-class early development services and site network from Phase I-IV.
The National Institute for Health and Care Research (NIHR)
The NIHR Life Sciences Industry Hub is your entry point to England’s integrated clinical research system, with coordinated access to UK-wide capability. The Industry Hub’s support is free of charge, funded by the UK Government, and designed to make the UK a globally competitive destination for commercial clinical research. We provide: Single national entry to NIHR – One conversation provides access to our entire integrated commercial trials pathway. Dedicated operational leadership – A named national lead coordinates delivery and manages dependencies across the system. Reliable, data-enabled feasibility – Coordinated once, using real-time capability and capacity to improve predictability. Smarter site selection – Intelligent study placement across health and care settings for speed, quality and performance. Faster start-up – Coordinated oversight of costing, contracting and assurance. Active performance management and escalation – Real-time oversight of set-up and recruitment, with clear escalation routes and time-bound resolution. Inclusive, scalable recruitment – Approaches that improve reach, diversity and reliability, including digitally-enabled and hybrid delivery models. Strategic partnership opportunities – Portfolio-level engagement and longer-term collaboration with the NIHR research system.
Taiwan Contract Research One-Stop Service
(1) To establish a leading preclinical R&D alliance in Taiwan. (2) To integrate the core strengths of five major R&D institutions in Taiwan: National Center for Biomodels (NCB) of the National Institutes of Applied Research, Biomedical Translation Research Center of Academia Sinica, Industrial Technology Research Institute (ITRI), Development Center for Biotechnology (DCB), and National Health Research Institutes. (3) To provide a complete one-stop CRO service, accelerating the translation and industrialization of innovative achievements in biotechnology and medicine.
SpeciLife Inc
SpeciLife is a biospecimen sourcing hub supporting pharma and biotech teams in translational and preclinical research. We provide access to high-quality, well-annotated human samples (FFPE, fresh and frozen tissues, biofluids, and cells) through established partnerships with a global network of hospitals, clinical centers, and biobanks. Our approach is collaborative and science-driven, with our internal scientific team closely involved in feasibility assessment, quality oversight, and study alignment. We support projects across key therapeutic areas including oncology, autoimmune, infectious, and neurodegenerative diseases.
SanaClis CRO
SanaClis CRO – Founded in 2000, SanaClis is a full-service global CRO with strong in-house clinical supply chain, logistics, and sourcing capabilities. We support clinical trials worldwide across the full study lifecycle and can operate as either a full-service or functional service provider, depending on sponsor needs. We have delivered clinical trial projects for sponsors ranging from virtual biotech to top 10 pharmaceutical companies, combining operational rigor with responsive execution and a focus on quality and predictable delivery. SanaClis provides CRO and clinical supply chain services across all therapeutic areas, with coverage across Europe (including the UK), USA (Americas) and Asia. We also bring deep operational experience in Central and Eastern Europe (CEE), supporting strong patient access and reliable site performance. To enable global distribution, SanaClis operates a network of privately owned, GMP- and GDP-certified depots strategically located worldwide. Our facilities support ambient and cold-chain storage, as well as packaging, labeling, and distribution services to protect product integrity throughout the IMP cold chain. CRO Services: Project Management, Clinical Monitoring, Site Management, Regulatory, Medical Writing, Data Management, Biostatistics, Pharmacovigilance, Medical Monitoring, Quality Management, Decentralized Trials. Clinical Supply Chain Services: Storage and Distribution, Secondary Packaging and Labelling, Global Strategic Sourcing, Qualified Person Services, Customs and Brokerage, SIMS – Inventory Management, Direct to Patient Services. Please reach out to Matt Delaney, Vice President of Business Development for the Americas region, email: matt.delaney@sanaclis.com or by phone at: 1 805 798-0060. Matt resides in San Diego, Ca.
Richmond Pharmacology
Richmond Pharmacology is a leading UK-based contract research organisation (CRO) providing comprehensive clinical research services from First-in-Human (FIH) and First-in-Patient (FIP) through to Phase III studies. For over two decades, we have partnered with pharmaceutical and biotechnology companies globally — particularly across the United States, Europe, and Japan — to deliver faster answers and empower smarter development decisions. Operating from a state-of-the-art clinical pharmacology unit in London, we integrate real-world clinical expertise, regulatory foresight, and operational excellence to support the successful delivery of complex clinical development programmes. Faster Answers for Smarter Decisions At Richmond Pharmacology, “Faster Answers” is our guiding principle. Through a combination of expert-led study design, agile operational models, and strategic regulatory insight, we enable sponsors to generate high-quality data earlier, accelerating programme timelines and reducing development risk. Our Core Expertise Includes: First-in-Human (FIH), First-in-Patient (FIP), and Clinical Development up to Phase III: Extensive experience managing trials from initial dosing through proof-of-concept and pivotal Phase III studies, across a broad range of therapeutic areas. Gene Editing and Gene Silencing Studies: Richmond Pharmacology is proud to support cutting-edge research in advanced therapeutic modalities, including CRISPR-Cas9 genome editing and RNA interference (RNAi)-based gene silencing, helping innovators bring transformative medicines to patients faster. Patient and Healthy Volunteer Studies: Our work spans both healthy volunteer and patient-focused research, with a strategic emphasis towards increasing patient-centric trials to better reflect real-world treatment needs. Rare and Orphan Disease Trials: We are recognised for our ability to design and conduct trials for rare and ultra-rare conditions, navigating recruitment and operational complexities with sensitivity and precision. Bridging Studies: Richmond Pharmacology is a leader in Japanese–European bridging studies, providing critical data to support global strategies. Cardiovascular, Metabolic, and Central Nervous System (CNS) Disorders: Specialist expertise in diseases such as cardiovascular disease (CVD), chronic kidney disease (CKD), hyperlipidaemia, non-alcoholic steatohepatitis (NASH), diabetes, and neurodegenerative or psychiatric disorders. Complex and Adaptive Trial Designs: Expertise in designing seamless adaptive protocols, umbrella trials, and novel methodologies that optimise development pathways while preserving scientific and regulatory integrity. Patient and Public Involvement (PPI): We embed Patient and Public Involvement across study planning and execution, ensuring trial designs are informed by patient perspectives to enhance engagement, experience, and outcomes. Regulatory Strategy and Scientific Consultancy: Richmond Pharmacology provides scientific and regulatory consultancy services, guiding sponsors through regulatory interactions and optimising study designs for approvals in the UK, US, and Europe. Why Partner with Richmond Pharmacology? Our experienced team, operational flexibility, and focus on scientific excellence make Richmond Pharmacology a trusted partner for companies seeking faster, smarter clinical development. Whether advancing a novel genetic therapy, accelerating a rare disease treatment, or bridging critical data across regions, we provide the solutions needed to move innovative therapies forward. For more information, please visit www.richmondpharmacology.com
PSC Biotech
Founded in 1996, PSC Biotech Corporation is a global organization that has spent over two decades providing life science services and solutions through our professional service consultancy for CQV, CSV, auditing, IT services, and much more. PSC Software provides inspection/audit management and eQMS services and BioTechnique provides CRDMO services. We also distribute equipment (Lives International data loggers and thermal mapping systems). Since its inception, PSC has served as a strategic partner to emerging and established life science companies, helping them bring their life-saving products to market. | PSC Biotech® is a global specialty life sciences consultancy firms, supporting over 1000 clients in more than 35 countries. PSC Biotech Corporation® provides life science services and solutions through our professional service consultancy (CQV, CSA/CSV, Audit, and much more.) PSC Software® provides inspection management and electronic quality management systems that enable businesses to stay compliant while effectively and efficiently delivering products to market. PSC Software® has 4 proprietary, 21 CFR Part 11 compliant, cloud-based systems that accelerate and streamline quality processes. BioTechnique® is a division of PSC Biotech Corporation®. BioTechnique® is a Contract Research, Development, and Manufacturing Organization (CRDMO) that provides lyophilization and therapeutic sterile injectable fill-finish solutions to cater to both large and small investigational/clinical stage or commercial batch sizes. BioTechnique® provides a comprehensive platform for success, beginning with Formulation Studies, extending through Analytical and Formulation Development, and culminating in Product Launch (clinical or commercial). | . | BioTechnique is a CRDMO, pharmaceutical manufacturing facility located in York, PA. A highly potent sterile injectable and clinical oncolytics manufacturing company dedicated to providing cytotoxic and high potency sterile injectable fill-finish services. Our project management and client services staff work closely with clients to meet all their manufacturing needs. We provide formulation and compounding, fill-finish, lyophilization, shipping, storage, and 3rd party logistics for a wide variety of liquid injectables. BioTechnique utilizes our expertise to create process designs for client product needs. To learn more, visit www.biotechnique.com